Polycystic ovarian syndrome - Exploring the therapeutic and biomedical insights into the role of silver nanoparticles
Abstract
A prevalent endocrinopathy affecting reproductive-age women is polycystic ovarian syndrome (PCOS), which affects around 5-20 % of these individuals. PCOS is closely linked to the following causes: immunological, endocrine, and reactive oxygen species (ROS). Plant extracts are used in the synthesis of silver nanoparticles (AgNPs), which are employed for PCOS treatment. Ag NPs can regulate the hormonal imbalance, reducing pro-inflammatory cytokines and ovarian cysts in PCOS. Conventional medicines, such as metformin, clomiphene citrate, letrozole, flutamide, and rosiglitazone, can regulate menstrual irregularities, improve ovulation, reduce insulin resistance, and decrease androgen levels, but may also cause various side effects. As a result, AgNPs are more effective at optimized doses in the short term used in the treatment of PCOS. The present article provides an uncommon overview of the mechanism of action and safety of AgNPs that are biosynthesized to treat the PCOS condition. The review includes evidence from insulin, inflammation, oxidative processes, neuroendocrine factors and cystogenic pathways to combine and provide an overview. The review also discusses how to approach toxicity, especially dose-dependent, and the reproductive safety of AgNPs and their translational limitations to define the boundaries of AgNPs in the treatment of PCOS.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.